Impact of 12 weeks oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: a prospective, double-blind, placebo-controlled, monocentric clinical trial of phase IV

Trial Profile

Impact of 12 weeks oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: a prospective, double-blind, placebo-controlled, monocentric clinical trial of phase IV

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Oct 2014

At a glance

  • Drugs Niacin (Primary)
  • Indications Coronary artery disease; Dyslipidaemias
  • Focus Pharmacodynamics
  • Acronyms INEF
  • Most Recent Events

    • 05 Sep 2007 Results have been presented
    • 12 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top